期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

获得深层分子学反应：慢性髓性白血病治疗的新目标？ 被引量：2

Deep molecular response： the new target of treatment ofchronic myeloid leukemia？
原文传递
导出
摘要 酪氨酸激酶抑制剂（TKI）的问世，大大降低了慢性髓性白血病（CML）患者疾病进展的风险，显著延长了患者生存期。
作者 江倩
机构地区 北京大学人民医院、北京大学血液病研究所
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第2期176-179,共4页 Chinese Journal of Hematology
基金 北京市科学技术委员会基金（Z131100004013026）：北京大学人民医院研究与发展基金（RDC2012-20）
关键词 慢性髓性白血病 分子学 酪氨酸激酶抑制剂 治疗 反应 疾病进展 显著延长 生存期
分类号 R733.72 [医药卫生—肿瘤]
  • 相关文献

参考文献34

  • 1Gambacorti- Passerini C, Antolini L, Mahon FX, et al. Multi?center independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib[J].J Natl Cancer Inst, 20 II, I 03 (7) :553-561.
  • 2CortesJE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJ J].J Clin Oncol, 2010, 28(3 ):424-430.
  • 3CortesJE,Jones D, O'Brien S, et al. Nilotinib as front-line treat?ment for patients with chronic myeloid leukemia in early chron?ic phaselJ],J Clin Oncol,2010,28 (3 ):392-397.
  • 4Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia[J]. N EnglJ Med,201 0,362(24) :2251-2259.
  • 5CortesJE,Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic- phase chronic myeloid leukemia[lJ.J Clin Oncol, 2010, 28(3 ):398-404.
  • 6Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus ima?tinib in newly diagnosed chronic-phase chronic myeloid leuke?mia] J]. N EnglJ Med, 2010, 362(24):2260-2270.
  • 7CortesJ, Hochhaus A, Hughes T, et al. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia[lJ.J Clin Oncol, 2011, 29 (5): 524-531.
  • 8Baccarani M, Deininger MW, Rosti G, et al. European Leukemi?aNet recommendations for the management of chronic myeloid leukemia: 2013[J]. Blood, 2013,122(6):872-884.
  • 9Hehlmann R, Lauseker M,Jung- Munkwitz S, et al. Tolerability?adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-a in newly diagnosed chronic myeloid leukemia[lJ.J Clin Oneal, 2011, 29(12):1634-1642.
  • 10Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaN?et criteria for failure or suboptimal response reliably identify pa- tients with CML in early chronic phase treated with imatinib whose eventual outcome is poor[J]. Blood, 2008, 112 (12): 4437-4444.

同被引文献17

  • 1Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacyand improves tolerability in imatinib-resistant and- intolerant chronic-phase chronic myeloid leukemia [J]. J Clin Oncol, 2008, 26( 19):3204-3212. doi: 10.1200/JCO.2007.14.9260.
  • 2Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study [J]. Blood, 2014, 123 ( 15):2317-2324. doi: 10.1182/blood-2013-10-532341.
  • 3Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasat- inib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intol- erant to imatinib: 15-month median follow-up [J]. Blood, 2009, 113(25):6322-6329. doi: 10.1182/blood-2008-11-186817.
  • 4. Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib- resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily [J]. Cancer, 2010, 116 (16):3852-3861. doi: 10.1002/cncr.25123.
  • 5Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results [J]. Blood, 2011, 117(4):1141-1145. doi: 10.1182/blood-2010- 03 -277152.
  • 6Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy [J]. Blood, 2010, 116 (25):5497- 5500. doi: 10.1182/blood-2010-06-291922.
  • 7Qin Y, Chen S, Jiang B, et al. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients [J]. Ann Hematol, 2011, 90 ( 1 ):47-52. doi: 10.1007/s00277-010-1039-5.
  • 8Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet [J]. J Clin Oncol, 2009, 27 (35):6041- 6051. doi: 10.1200/JCO.2009.25.0779.
  • 9Baccarani M, Deininger MW, Rosti G, et al. European Leukemi- aNet recommendations for the management of chronic myeloid leukemia: 2013 [J]. Blood, 2013, 122(6):872-884. doi: 10.1182/ blood-2013-05-501569.
  • 10Qin YZ, Jiang Q, Jiang H, et al. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL (IS) or log reduction from the baseline level? [J]. Leuk Res, 2013, 37 (9) : 1035- 1040. doi: 10.1016/j. leukres.2013.06.003.

引证文献2

二级引证文献9

中华血液学杂志
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部